{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T03:56:10Z","timestamp":1772942170143,"version":"3.50.1"},"reference-count":26,"publisher":"BMJ","issue":"3","funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"crossref","award":["12\/35\/64"],"award-info":[{"award-number":["12\/35\/64"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2023,2,15]]},"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec><jats:title>Background\/aims<\/jats:title><jats:p>To investigate the clinical effectiveness of adjunctive triamcinolone acetonide (TA) given at the time of vitreoretinal surgery following open globe trauma (OGT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A phase 3, multicentre, double-masked randomised controlled trial of patients undergoing vitrectomy following OGT comparing adjunctive TA (intravitreal and subtenons) against standard care (2014\u20132020). The primary outcome was the proportion of patients with at least 10 Early Treatment Diabetic Retinopathy Study (ETDRS) letter improvement in corrected visual acuity (VA) at 6 months. Secondary outcomes included: change in ETDRS, retinal detachment (RD) secondary to PVR, retinal reattachment, macular reattachment, tractional RD, number of operations, hypotony, elevated intraocular pressure and quality of life.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>280 patients were randomised over 75 months, of which 259 completed the study. 46.9% (n=61\/130) of patients in the treatment group had a 10-letter improvement in VA compared with 43.4% (n=56\/129) of the control group (difference 3.5% (95% CI \u22128.6% to 15.6%), OR=1.03 (95% CI 0.61 to 1.75), p=0.908)). Secondary outcome measures also failed to show any treatment benefit. For two of the secondary outcome measures, stable complete retinal and macular reattachment, outcomes were worse in the treatment group compared with controls, respectively, 51.6% (n=65\/126) vs 64.2% (n=79\/123), OR=0.59 (95% CI 0.36 to 0.99), and 54.0% (n=68\/126) vs 66.7% (n=82\/123), OR=0.59 (95% CI 0.35 to 0.98), for TA vs control.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The use of combined intraocular and sub-Tenons capsule TA is not recommended as an adjunct to vitrectomy surgery following OGT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02873026\">NCT02873026<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjo-2022-322787","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T18:20:47Z","timestamp":1677522047000},"page":"440-448","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Randomised controlled trial of adjunctive triamcinolone acetonide in eyes undergoing vitreoretinal surgery following open globe trauma: The ASCOT study"],"prefix":"10.1136","volume":"108","clinical-trial-number":[{"clinical-trial-number":"nct02873026","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8837-9910","authenticated-orcid":false,"given":"Edward J","family":"Casswell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6113-1173","authenticated-orcid":false,"given":"Suzie","family":"Cro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria R","family":"Cornelius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tapiwa M","family":"Zvobgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhiannon","family":"Tudor Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victory","family":"Ezeofor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethany","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9793-7224","authenticated-orcid":false,"given":"Syed Mohammed","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0935-3713","authenticated-orcid":false,"given":"Catey","family":"Bunce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Charteris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,2,27]]},"reference":[{"key":"2024022109050588000_108.3.440.1","doi-asserted-by":"publisher","DOI":"10.1076\/opep.5.3.143.8364"},{"key":"2024022109050588000_108.3.440.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.06.045"},{"key":"2024022109050588000_108.3.440.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.10.013"},{"key":"2024022109050588000_108.3.440.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(97)30167-5"},{"key":"2024022109050588000_108.3.440.5","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9394(81)90171-9"},{"key":"2024022109050588000_108.3.440.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)75196-7"},{"key":"2024022109050588000_108.3.440.7","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-199701000-00009"},{"key":"2024022109050588000_108.3.440.8","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-307347"},{"key":"2024022109050588000_108.3.440.9","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ophtha.2017.01.021","article-title":"Slow-release dexamethasone in proliferative vitreoretinopathy: a prospective, randomized controlled clinical trial","volume":"124","author":"Banerjee","year":"2017","journal-title":"Ophthalmology"},{"key":"2024022109050588000_108.3.440.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-011-1919-y"},{"key":"2024022109050588000_108.3.440.11","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-016-1445-7","article-title":"Adjunctive intraocular and peri-ocular steroid (triamcinolone acetonide) versus standard treatment in eyes undergoing vitreoretinal surgery for open globe trauma (Ascot): study protocol for a phase III, multi-centre, double-masked randomised controlled trial","volume":"17","author":"Banerjee","year":"2016","journal-title":"Trials"},{"key":"2024022109050588000_108.3.440.12","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-016-1464-4","article-title":"A phase III, multi-centre, double-masked randomised controlled trial of adjunctive intraocular and peri-ocular steroid (triamcinolone acetonide) versus standard treatment in eyes undergoing vitreoretinal surgery for open globe trauma (Ascot): statistical analysis plan","volume":"17","author":"Lo","year":"2016","journal-title":"Trials"},{"key":"2024022109050588000_108.3.440.13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41433-019-0699-1","article-title":"Proliferative vitreoretinopathy: revised concepts of pathogenesis and adjunctive treatment","volume":"34","author":"Charteris","year":"2020","journal-title":"Eye (Lond)"},{"key":"2024022109050588000_108.3.440.14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0161-6420(95)31009-3","article-title":"Visual outcome and ocular survival after penetrating trauma. A clinicopathologic study","volume":"102","author":"Esmaeli","year":"1995","journal-title":"Ophthalmology"},{"key":"2024022109050588000_108.3.440.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-4182(05)80052-3"},{"key":"2024022109050588000_108.3.440.16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3928\/15428877-20070901-02","article-title":"Triamcinolone acetonide as an adjuvant in the surgical treatment of retinal detachment with proliferative vitreoretinopathy","volume":"38","author":"Cheema","year":"2007","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"2024022109050588000_108.3.440.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.05.016"},{"key":"2024022109050588000_108.3.440.18","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/s41433-019-0408-0","article-title":"Intraocular application of mitomycin C to prevent proliferative vitreoretinopathy in perforating and severe intraocular foreign body injuries","volume":"33","author":"Assi","year":"2019","journal-title":"Eye (Lond)"},{"key":"2024022109050588000_108.3.440.19","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1093\/annonc\/mdx410","article-title":"Thursday\u2019s child has far to go\u2019-interpreting subgroups and the STAMPEDE trial","volume":"28","author":"Spears","year":"2017","journal-title":"Ann Oncol"},{"key":"2024022109050588000_108.3.440.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr077003"},{"key":"2024022109050588000_108.3.440.21","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/sj.eye.6700194","article-title":"Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology","volume":"16","author":"Charteris","year":"2002","journal-title":"Eye (Lond)"},{"key":"2024022109050588000_108.3.440.22","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.79.10.953"},{"key":"2024022109050588000_108.3.440.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(98)00115-9"},{"key":"2024022109050588000_108.3.440.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2004.05.036"},{"key":"2024022109050588000_108.3.440.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.08.042"},{"key":"2024022109050588000_108.3.440.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(01)00589-9"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2022-322787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T17:08:15Z","timestamp":1708535295000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2022-322787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,27]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,2,21]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1136\/bjo-2022-322787"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2022-322787","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,27]]}}}